Insulin prices have been rising annually in the U.S. for years, with the country maintaining the highest average price for insulin around the world by a staggering margin. The Affordable Insulin Now Act, which will go into effect in late 2022, will offer reprieve for many Americans by capping copays. However, the legislation does not lower the actual price of insulin, leaving behind the many American diabetics who do not have health insurance.
To explore this further, CharityRx commissioned a survey of 2,000 U.S. adults aged 18 and over who have diabetes and/or provide care to someone with diabetes, including 1,000 insured and 1,000 uninsured adults. The analysis is accompanied by third-party data sourced from the CDC’s United States Diabetes Surveillance System and the National Diabetes Statistics Report.
The study found, when comparing the U.S. to countries around the world, the cost of insulin in the U.S. is 8 times higher than the combined average of other high-income nations. The exorbitant pricing of insulin in the U.S. has forced many diabetics and their caregivers to make difficult decisions and compromises that put their health and/or livelihood at risk.
- The Financial Burden of U.S. Insulin Pricing on the American Diabetic Community. CharityRx. Jun 1 2022.